Last but not least is Schering-Plough who falls 15th on the r&d budget list ($1.65 bn EUR) and 16th in over all sales for 2006. After a number of bad years Schering has put itself back in the running with various moves that have revitalized its drug pipeline. Those moves include the purchase of Azko Nobel’s Organon which added five late-stage drugs to the pipeline. Also, the FDA recently accepted Schering’s application for asenapine which is indicated for schizophrenia and bipolar disorder.
Pending Approval:
ASMANEX - Asthma (Japan), Pediatric Asthma
CLARITIN/Singulair2 - Seasonal Allergic Rhinitis
NASONEX - Allergic Rhinitis (Japan) NOXAFIL - Serious Fungal Infections
Phase III:
Acadesine - Ischemia-Reperfusion Injury
ASENTAR - Prostate Cancer
Golimumab (CNTO 148) - Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis
Mometasone/Formoterol Combination - Asthma, COPD
SARASAR - Myelodysplastic Syndrome
Sublingual Tablet-Based Immunotherapy - Grass Pollen Allergies
Thrombin Receptor Antagonist - ACS / Secondary Prevention
Vicriviroc - HIV Infection
CAELYX1 - Multiple Myeloma (EU)
INTEGRILIN - Early Acute Coronary Syndrome
NASONEX - Rhinosinusitis
PEGINTRON - Malignant Melanoma
TEMODAR - Metastatic Melanoma
VYTORIN2 - Aortic Stenosis, Renal Disease, High Risk Hypercholesterolemia, Acute Coronary Syndrome
ZETIA2 - Pediatric Primary Hypercholesterolemia
[Source: FierceBioTech]
.jpg)
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 14, 2007 2:18 PM | Permalink to Trackback